Kancera AB intends to provide new information about the company's pharmaceutical projects during April in a prospectus that forms part of a proposed new share issue. For this reason, Kancera now communicates the following information: Kanceras HDAC6 inhibitor KAN0440262...
Read MoreThis is a translation of a Press Release in Swedish Stockholm 2018-04-03
Read MorePERIOD 1 JAN – 31 DEC 2017 IN BRIEF • Net turnover for the period amounted to SEK 0.1 million (0.3 million). For the fourth quarter, turnover amounted to 0.0 MEK (0.1 M). • R & D expenses for the period amounted to...
Read MoreKancera AB (publ) hereby reports results from a Phase I study in healthy subjects with the immunoregulating drug candidate KAND567. The study shows that KAND567 is safe and well-tolerated up to 500 mg twice daily for 7 days. The...
Read MoreKancera AB (publ) reports that the Phase I study in the Fractalkine project has been completed in accordance with study protocols. In the study, drug characteristics, safety and tolerability have been documented for KAND567 in 62 healthy subjects. The...
Read MoreKancera AB (publ) has previously announced that the company controls patents and rights to the Fractalkine project, including KAND567, in all diseases except lung diseases. Agreements with AstraZeneca AB and Acturum Real Estate AB now give Kancera AB full...
Read MoreAccording to the agreement with Acturum Real Estate AB, the second partial payment for the Fractalkine project is due when the drug candidate KAND567 has been given to a certain number of subjects in the ongoing Phase Ia study.Therefore,...
Read MorePERIOD 1 JAN – 30 SEPT 2017 IN BRIEF • R&D expenses for the period amounted to SEK 39.8 million (13.3 million ), of which the third quarter amounted to SEK 14.7 million (4.6 million ) • Operating profit for the period amounted to...
Read MoreKancera hereby reports that the company's ROR inhibitor KAN0441571 effectively eliminates ROR1-bearing leukemic cells in a mouse model of human chronic lymphocytic leukemia.
Read MoreKancera, a development company focused on cancer therapy and Recipharm, a leading contract development and manufacturing organisation (CDMO), have signed a contract for the development and manufacture of the pharmaceutical candidate KAND567.
Read More